Evidence map›Paper›PMID 28941314›Full record

Trial reportDiabetes, obesity & metabolism2018

Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity.

Julie B Hjerpsted, Anne Flint, Ashley Brooks, Mads B Axelsen, Trine Kvist, John Blundell

2 registry-linked trialsOpen access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02079870. Cited by 119 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 8 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02079870 phase1completed

A Single-centre, Randomised, Double-blind Two-period Cross-over Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

Ran2014Enrolled30Registered outcomes6Posted comparisons0ConditionsDiabetes, Metabolism and Nutrition Disorder, ObesityArmsPlacebo, semaglutide
PMID 28266779other papers from this trial
Open the trial in the graph
NCT07617155 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Effects of GLP-1 Agonists on Prevention of HTG-Induced Acute Pancreatitis Recurrence: Protocol for a Randomized Clinical Trial

TypeinterventionalSponsorPeking Union Medical College HospitalRan2026 to 2028Enrolled396ConditionsHypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis, Pancreatitis Relapsing, HypertriglyceridemiaArmsSemaglutide, Placebo (Normal Saline)
3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 8 syntheses or guidelines pooled it, 215 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Julie B HjerpstedNovo Nordisk A/S, Søborg, Denmark.ORCID 0000-0002-6938-786X
Anne FlintNovo Nordisk A/S, Søborg, Denmark.
Ashley BrooksCovance Clinical Research Unit Ltd, Leeds, UK.
Mads B AxelsenNovo Nordisk A/S, Søborg, Denmark.
Trine KvistNovo Nordisk A/S, Søborg, Denmark.
John BlundellInstitute of Psychological Sciences, Faculty of Medicine and Health, University of Leeds, Leeds, UK.ORCID 0000-0002-7085-9596
Novo Nordisk (Denmark) · DKCovance (United Kingdom) · GBUniversity of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the effects of semaglutide on fasting and postprandial glucose and lipid responses, and on gastric emptying. MATERIALS AND

methodsThis was a randomized, double-blind, placebo-controlled, 2-period, crossover trial. Subjects with obesity (N = 30) received once-weekly subcutaneous semaglutide, dose-escalated to 1.0 mg, or placebo. After each 12-week treatment period, glucose and lipid metabolism were assessed before and after standardized meals. Gastric emptying (paracetamol absorption test) and peptide YY (PYY) response were also assessed.

resultsSemaglutide treatment significantly lowered fasting concentrations of glucose and glucagon, and increased insulin vs placebo (estimated treatment ratio: 0.95 [95% confidence interval: 0.91, 0.98]; 0.86 [0.75, 0.98]; 1.45 [1.20, 1.75], respectively). Postprandial glucose metabolism significantly improved with semaglutide vs placebo (incremental area under the curve 0 to 5 hours [iAUC

conclusionSemaglutide improved fasting and postprandial glucose and lipid metabolism. Overall gastric emptying was similar to that with placebo; however, the observed first-hour delay with semaglutide may contribute to a slower entry of glucose into the circulation.

Indexed as

AdultBlood GlucoseCross-Over StudiesDiabetes Mellitus, Type 2Double-Blind MethodDrug Administration ScheduleFastingFemaleGastric EmptyingGlucagon-Like PeptidesHumansHypoglycemic AgentsInjections, SubcutaneousLipid MetabolismMaleObesityBlood GlucoseGlucagon-Like PeptidesHypoglycemic AgentsSemaglutideGLP-1 analogueglucose metabolismincretin therapyinsulin analoguesobesity therapyphase I-II study

Identifiers

PMID28941314
PMCPMC5836914
OpenAlexW2756558030

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.